Last reviewed · How we verify
shark cartilage extract AE-941 — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
shark cartilage extract AE-941 (shark cartilage extract AE-941) — AEterna Zentaris. AE-941, a shark cartilage extract, is thought to inhibit angiogenesis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| shark cartilage extract AE-941 TARGET | shark cartilage extract AE-941 | AEterna Zentaris | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- shark cartilage extract AE-941 CI watch — RSS
- shark cartilage extract AE-941 CI watch — Atom
- shark cartilage extract AE-941 CI watch — JSON
- shark cartilage extract AE-941 alone — RSS
Cite this brief
Drug Landscape (2026). shark cartilage extract AE-941 — Competitive Intelligence Brief. https://druglandscape.com/ci/shark-cartilage-extract-ae-941. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab